# Pharming Group (PHAR) — News

PHAR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/phar/news

## Recent headlines

- [Pharming presents positive phase II topline data for leniolisib](https://www.ainvest.com/news/pharming-presents-positive-phase-ii-topline-data-leniolisib-2610) — AInvest Wire, Oct 14, 2026
- [Pharming Group N.V. - Topline results from separate phase II trial in cvid expected in November](https://www.ainvest.com/news/pharming-group-topline-results-separate-phase-ii-trial-cvid-expected-november-2610) — AInvest Wire, Oct 14, 2026
- [Pharming Group N.V. - Leniolisib was generally well-tolerated across all 4 genotypes](https://www.ainvest.com/news/pharming-group-leniolisib-generally-tolerated-4-genotypes-2610) — AInvest Wire, Oct 14, 2026
- [Pharming Group N.V - All phase II leniolisib study completers enrolled in three-year extension study](https://www.ainvest.com/news/pharming-group-phase-ii-leniolisib-study-completers-enrolled-year-extension-study-2610) — AInvest Wire, Oct 14, 2026
- [Pharming Group N.V - Improvement in liver stiffness observed in phase II leniolisib trial](https://www.ainvest.com/news/pharming-group-improvement-liver-stiffness-observed-phase-ii-leniolisib-trial-2610) — AInvest Wire, Oct 14, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).